Summary
The inhibition of serotonin uptake by platelets has been measured in blood from 20 patients on amitriptyline (50–225 mg daily), 14 patients on clomipramine (25–200 mg daily), and in an untreated group of 21 depressed patients. A complete kinetic analysis was carried out in each patient. Using the increase in the kinetic parameter Km as a measure of uptake inhibition, there was a high correlation between the daily dose and inhibition within each drug group, clomipramine being about 10 times more potent than amitriptyline. The inhibition did not vary with age, sex, duration of treatment (up to 3 years), or concomitant use of moderate doses of benzodiazepines, neuroleptics or lithium. In the amitriptyline group the inhibition was significantly smaller in smokers than in non-smokers. The kinetic parameter Vmax was essentially unchanged in the amitriptyline group, and was markedly reduced in the clomipramine group, but without any correlation with dose. The mixed competitive-noncompetitive effect of clomipramine confirms previous in vitro findings.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alexanderson, B., Price Evans, D. A., Sjöqvist, F.: Steady-state plasma levels of nortriptyline in twins: Influence of genetic factors and drug therapy. Br. Med. J.1969/IV, 764–768
Borgå, O., Azarnoff, D. L., Forshell, G. P., Sjöqvist, F.: Plasma protein binding of tricyclic antidepressants in man. Biochem. Pharmacol.18, 2135–2143 (1969)
Borgå, O., Hamberger, B., Malmfors, T., Sjöqvist, F.: The role of plasma binding in the inhibitory effect of nortriptyline on the neuronal uptake of norepinephrine. Clin. Pharmacol. Ther.11, 581–588 (1970)
Carlsson, A., Fuxe, K., Ungerstedt, U.: The effect of imipramine of central 5-hydroxytryptamine neurons. J. Pharm. Pharmacol.20, 150–151 (1968)
Glassman, A. H.: Plasma levels of imipramine and clinical outcome. Psychopharmacol. Bull.13/4, 50–51 (1977)
Hamberger, B., Tuck, J. R.: Effect of tricyclic antidepressants on the uptake of noradrenaline and 5-hydroxytryptamine by rat brain slices incubated in buffer or human plasma. Eur. J. clin. Pharmacol.5, 229–235 (1973)
Hammer, W., Sjöqvist, F.: Plasma levels of monomethylated tricyclic antidepressants during treatment with imipraminelike compounds. Life Sci.6, 1895–1903 (1967)
Lapin, I. P., Oxenkrug, G. F.: Intensification of the central serotoninergic processes as a possible determinant of the thymoleptic effect. Lancet1979/I, 132–136
Lemberger, L., Rowe, H., Carmichael, R., Oldham, S., Horng, J. S., Bymaster, F. B., Wong, D. T.: Pharmacologic effects in man of a specific serotonin-reuptake inhibitor. Science199, 436–437 (1978)
Lingjærde, O.: Effect of doxepin on uptake and efflux of serotonin in human blood platelets in vitro. Psychopharmacology47, 183–186 (1976)
Lingjærde, O.: Platelet uptake and storage of serotonin. In: Serotonin in health and disease, Vol. 4. W. B. Essman (ed.), pp. 139–199. New York: Spectrum 1977a
Lingjærde, O.: Nomifensine symposium: Discussion after paper by R. Ehsanullah and P. Turner. Br. J. clin. Pharmacol.4, 165S-166S (1977b)
Lingjærde, O.: Inhibitory effect of clomipramine and related drugs on serotonin uptake in platelets: More complicated than previously thought. Psychopharmocology61, 245–249 (1979)
Mahler, H. R., Cordes, E. H.: Biological chemistry. New York: Evanston 1967
Marshall, E. F., Stirling G. S., Tait, A. C., Todrick, A.: The effect of iproniazide and imipramine on the blood platelet 5-hydroxytryptamine level in man. Br. J. Pharmacol.15, 35–41 (1960)
Murphy, D. L., Colburn, R. W., Davis, J. M., Bunney, W. E.: Imipramine and lithium effects on biogenic amine transport in depressed and manic-depressed patients. Am. J. Psychiatry127, 339–345 (1970)
Norman, T. H., Burrows, G. D., Maguire, K. P., Rubinstein, G., Scoggins, B. A., Davies, B.: Cigarette smoking and plasma nortriptyline levels. Clin. Pharmacol. Ther.21, 453–456 (1977)
Perel, J. M., Hurvic, M. J., Kanzler, M. B.: Pharmacodynamics of imipramine in depressed patients. Psychopharmacol. Bull.11/4, 16–17 (1975)
Rysanek, K., Vitek, V., Svehla, C.: Serotonin level in human and animal thrombocytes after imipramine and propazepine administration. Act. Nerv. Super.7, 261–262 (1965)
Tuck, J. R., Punell, G.: Uptake of (3H)5-hydroxytryptamine and (3H)noradrenaline by slices of rat brain incubated in plasma from patients treated with chlorimipramine, imipramine or amitriptyline. J. Pharm. Pharmacol.25, 573–574 (1973)
Ziegler, V. E., Meyer, D. A., Rosen, S. H., Knesevich, J. H., Biggs, J. T.: Amitriptyline dosage schedule, sampling time and tricyclic plasma levels. Br. J. Psychiatry131, 168–171 (1977)
Åsberg, M., Thorén, P., Träskman, L., Bertilsson, L., Ringberger, V.: “Serotonin depression” — A biochemical subgroup within the affective disorders? Science191, 478–480 (1976)
Åsberg, M., Ringberger, V., Sjöqvist, F., Thorén, P., Träskman, L., Tuck, J. R.: Monoamine metabolites in cerebrospinal fluid and serotonin uptake inhibition during treatment with chlorimipramine. Clin. Pharmacol. Ther.21, 201–207 (1977)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lingjærde, O. Inhibition of platelet uptake of serotonin in plasma from patients treated with clomipramine and amitriptyline. Eur J Clin Pharmacol 15, 335–340 (1979). https://doi.org/10.1007/BF00558437
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00558437